2-Phenyl-Indole Compounds as PGD2 Receptor Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic conditions such as allergic rhinitis, asthma, and conjunctivitis are inadequate in effectively managing symptoms due to the role of prostaglandin D2 (PGD2) in mediating inflammatory responses, as existing therapies do not sufficiently target the PGD2 receptor.
Innovation Solution
Development of 2-phenyl-indole compounds that act as prostaglandin D2 receptor antagonists, which are incorporated into pharmaceutical compositions to inhibit the PGD2 receptor, thereby reducing inflammatory responses and alleviating symptoms of allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat allergic conditions, then treatment is provided, but the therapies do not sufficiently target the PGD2 receptor and fail to effectively manage symptoms
Solution Approach 1:
The invention changes the chemical structure parameters by developing 2-phenyl-indole compounds with specific molecular characteristics that enable selective binding to the PGD2 receptor. This structural parameter change allows the compound to effectively target the receptor, resolving the contradiction between treatment effectiveness and targeting capability.
2Reliability
If PGD2 receptor antagonists are developed to target the receptor specifically, then symptom management is improved, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
The invention extracts and isolates the specific functional component (2-phenyl-indole compound) that provides PGD2 receptor antagonism. By focusing on this single active ingredient with well-defined chemical structure, the composition achieves effective symptom management without unnecessary complexity, as the compound itself contains all necessary pharmacological properties.
3Object-affected harmful factors
If current treatments are used for allergic rhinitis, asthma, and conjunctivitis, then general symptom relief is provided, but inflammatory responses mediated by PGD2 are not sufficiently inhibited
Solution Approach 1:
The 2-phenyl-indole compound acts as an intermediary substance that blocks the interaction between PGD2 and its receptor. This intermediary mechanism specifically inhibits PGD2-mediated inflammatory responses without affecting other physiological pathways, thereby effectively addressing the harmful inflammatory factor while maintaining reliable efficacy.
Data Source
AI summary
The present invention is directed to 2-phenyl-indole compounds (A), their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.